Answers are grounded in this paper and cite their sources.
SUMMARY: In patients with multiple myeloma, completion of mRNA-based vaccination schemes failed to yield detectable SARS-CoV-2 Omicron-neutralizing antibodies and S1-RBD-specific CD8+ T cells in approximately 60% and 80% of the cases, respectively. Patients who develop breakthrough infections exhibited very low levels of live-virus neutralizing antibodies and the absence of follicular T helper cells. See related article by Azeem et al., p. 106 (9). See related article by Chang et al., p. 1684 (10).
No takes yet. Share an insight, caveat, or question.
Zitvogel et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: